Interventions for lowering plasma homocysteine levels in dialysis patients-Reference-Cited by-同舟云学术

Interventions for lowering plasma homocysteine levels in dialysis patients

Published:2016-05-31 Issue:5 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Nigwekar Sagar U¹,Kang Amy²³,Zoungas Sophia⁴,Cass Alan³⁵,Gallagher Martin P³,Kulshrestha Satyarth⁶,Navaneethan Sankar D⁷,Perkovic Vlado³,Strippoli Giovanni FM⁸⁹¹⁰¹¹¹²,Jardine Meg J³¹³

Affiliation:

1. Harvard Medical School; Division of Nephrology, Massachusetts General Hospital, Scholars in Clinical Sciences Program; Boston MA USA

2. The University of Sydney; Sydney Medical School; Sydney NSW Australia

3. The George Institute for Global Health, The University of Sydney; Renal and Metabolic Division; Camperdown NSW Australia

4. Monash University; Diabetes and Vascular Research Program, Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine; Clayton VIC Australia

5. Menzies School of Health Research; PO Box 41096 Casuarina NT Australia 0811

6. University of Iowa Carver College of Medicine; Department of Nephrology; 200 Hawkins Drive-T307GH Iowa City IA USA 52242

7. Baylor College of Medicine; 1 Baylor Plaza Houston Texas USA 77030

8. The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145

9. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy

10. Diaverum; Medical Scientific Office; Lund Sweden

11. Diaverum Academy; Bari Italy

12. The University of Sydney; Sydney School of Public Health; Sydney Australia

13. Concord Repatriation General Hospital; Department of Renal Medicine; Hospital Road Concord NSW Australia 2139

Publisher

Wiley

Subject

Pharmacology (medical)

Reference259 articles.

1. The atherosclerosis and folic acid supplementation trial in CRF (ASFAST): rationale, design and baseline results [abstract no: 65];McGrath;Nephrology,2002

2. The atherosclerosis and folic acid supplementation trial in CRF (ASFAST): rationale, design and baseline results [abstract];McGrath;Journal of the American Society of Nephrology,2001

3. The effect of lowering homocysteine on haemodialysis vascular access outcomes: the ASFAST randomised placebo controlled trial [abstract no: SU-FC110];Polkinghorne;Journal of the American Society of Nephrology,2007

4. Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results;Zoungas;Nephrology,2004

5. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD;Zoungas;American Journal of Kidney Diseases,2007

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supplementation of Antioxidants in Chronic Kidney Disease: Clinical Necessity or Wishful Thinking? A Bench to Bedside Translational Research;Current Medicinal Chemistry;2024-06-20

2. Pathophysiological concepts and screening of cardiovascular disease in dialysis patients;Frontiers in Nephrology;2023-09-29

3. Homocysteine, Vitamin B12 and Folate Level: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders;Current Cardiology Reviews;2023-07

4. Plasma Homocysteine Levels and Cardiovascular Events in Patients With End-Stage Renal Disease: A Systematic Review;Cureus;2023-06-13

5. Demand for Water-Soluble Vitamins in a Group of Patients with CKD versus Interventions and Supplementation—A Systematic Review;Nutrients;2023-02-08